Communication between adipose tissue and the brain increases the risk of cognitive impairment in patients with insulin resistance through extracellular vesicles (EVs) containing microRNAs (miRNAs). Neurons could be damaged when these nucleotides reach the hippocampus guided by membrane proteins in prediabetic overweight people. Read More
Efforts at Abbvie Inc. to selectively target voltage-gated sodium channel subunit alpha Nav1.7 to treat pain led to the discovery of quinoline and quinolone agents and, through structure-activity relationship studies, the candidate product ABBV-318. While Nav1.7 potency could be achieved with earlier compounds, efforts were required to improve characteristics including hERG activity, pharmacokinetics and selectivity over Nav1.5, yielding compounds which blocked Nav1.7 as well as another target for treating pain, Nav1.8. Read More
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has identified son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12D mutant) interaction inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous syndrome, Costello syndrome, neurofibromatosis type 1, Noonan syndrome and Legius syndrome (neurofibromatosis type 1-like syndrome). Read More
Monte Rosa Therapeutics Inc. has received FDA clearance of its IND application for MRT-2359, a potent and selective GSPT1-directed molecular glue degrader (MGD). Read More
Molecure SA presented data on the discovery of the clinical candidate OATD-02, a first-in-class, highly potent dual arginase-1/2 (ARG1/2) inhibitor with excellent activity against intracellular ARG2, thereby holding promise as an immunotherapeutic for cancer. Read More
Shanghai Institute of Organic Chemistry and Zai Lab (US) LLC have described new receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, atopic dermatitis, psoriasis, inflammatory bowel disease, inflammation, macular degeneration, systemic lupus erythematosus and arthritis, among other disorders. Read More
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has presented new Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer. Read More
Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd. has synthesized new antibody-drug conjugates (ADC) or antigen binding fragments targeting claudin 18 (CLDN18) and linked to cytotoxic drug reported to be useful for the treatment of cancer. Read More
Nanotics LLC has established a research collaboration with Mass General Cancer Center (MGCC), a program of Massachusetts General Hospital (MGH), to develop Nanots that target the soluble forms of tumor necrosis factor (TNF) receptors (sTNF-Rs). Read More
Investigators described preclinical data for AZD-5462 (Astrazeneca plc/Mitsubishi Tanabe Pharma Corp.), a novel oral agonist of the relaxin family peptide receptor 1 (RXFP1), being developed for the treatment of cardiorenal disease.
Tenaya Therapeutics Inc. has received FDA clearance of its IND application to begin clinical testing of TN-301, a highly selective small-molecule inhibitor of histone deacetylase 6 (HDAC6) initially being developed for heart failure with preserved ejection fraction (HFpEF). Read More
Biovaxys Technology Corp. has announced that Millipore-Sigma, the contract manufacturer for its preclinical viral vaccine program, has completed the bioproduction and batch release endotoxin screening of BVX-1021, the company's vaccine for SARS-CoV, which is being used in the collaboration with The Ohio State University (OSU) to develop a pan-sarbecovirus vaccine. Read More
Evaxion Biotech A/S, in collaboration with UMass Chan Medical School, has received a grant from the U.S. National Institutes of Health (NIH) for the development of a lead vaccine candidate for gonorrhea. Read More
Shanghai Visonpharma Co. Ltd. has patented dihydropyrimidine compounds reported to be useful for the treatment of hepatitis B virus (HBV) infections. Read More
Tetra Bio-Pharma Inc. has signed an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 (onternabez) as a combination product with Qifenda (favipiravir) 400 mg, a commercial-stage broad-spectrum antiviral drug. Read More
The FDA has granted orphan drug designation to Iecure Inc.'s lead product candidate GTP-506, an investigational product for the treatment of ornithine transcarbamylase (OTC) deficiency. Read More
Argininosuccinic aciduria (ASA) is a disorder caused by argininosuccinate lyase (ASL) deficiency and is the second most common inherited urea cycle defect. Read More
Dysregulation of complement activation plays a key role in the pathophysiology of several diseases, which makes it an attractive therapeutic target. C3 has an important role and central position within the signaling cascade, and is a potential target for therapy. Read More
Previous research has demonstrated that the expression of the calcium-activated potassium channel (Kca 3.1) is higher in patients with idiopathic pulmonary fibrosis (IPF), and that genetic and pharmacological inhibition of Kca3.1 was able to prevent or attenuate fibrosis.
